ARJUNA Therapeutics announces the appointment of Dr Robert Barnes to the Board of Directors

LONDON - April 8, 2021 - PRLog -- ARJUNA Therapeutics, the European biotech start-up, announces the appointment of Dr Robert Barnes to the Board of Directors.

Dr Barnes is Group Head of Securities Trading at London Stock Exchange Group (LSEG) and CEO of Turquoise, the European share trading platform majority owned by LSEG. Prior to joining LSEG in 2013, Dr Barnes worked at UBS in various roles, including as a Managing Director, Equities, and founding CEO of UBS MTF. With more than 27 years of Capital Markets experience, he is an industry expert on market structures and has held a wide range of key advisory and policy roles in the financial services sector. Robert is a Chartered Fellow of the Chartered Institute for Securities & Investment and holds a PhD in Biotechnology from Cambridge University and a BA in Biochemical Sciences from Harvard.

Ross Breckenridge FRCP, PhD, CEO and Chairman of ARJUNA Therapeutics said: "I'm delighted that Robert has joined our Board. His broad and deep understanding of financial markets and the business world will be of great value to the company as we move into the clinic and beyond".

Dr Barnes said: "I am honoured to join the ARJUNA team and look forward to helping the company in its goal of changing the way cancer is treated."

ARJUNA Therapeutics is developing a novel small molecule platform, Therapeutic Molecular Clusters (TMCs), to address the largest unmet clinical needs in oncology.

Dr Robert Barnes – Biography

Employment

2013 – present London Stock Exchange Group (LSEG)

• 2021 – present Group Head of Securities Trading, Capital Markets, LSEG
• 2020 – present Director, Turquoise Global Holdings Europe B.V.
• 2017 – 2020 Global Head of Primary Markets, London Stock Exchange Group
• 2016 – 2017 Interim Head of Primary Markets, London Stock Exchange Group
• 2013 – present CEO, Turquoise Global Holdings Limited

2013 Anopolis Limited – Founder & Managing Director

1994 – 2013 UBS – Managing Director since 2005

• 2010 – 2013 CEO, UBS MTF
• 2009 – 2013 Global Equities Management
• 2006 – 2009 Equities Distribution Global Products, ETD
• 1994 – 2006 various, including positions in Equities, Risk Arbitrage, CEO Management Office, E-commerce

Education & professional qualifications

2010 Chartered Fellow of the Chartered Institute for Securities & Investment (CISI)
1994 Cambridge PhD, Biotechnology
1989 Harvard BA, Biochemical Sciences

For more information about Arjuna Therapeutics, visit our website:
http://www.arjunatherapeutics.com